Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., have submitted an application in Japan for an additional dosage and administration of LENVIMA (lenvatinib) in combination with WELIREG (belzutifan) for the treatment of unresectable or metastatic renal cell carcinoma (RCC) that has progressed after chemotherapy. The application is based on the Phase 3 LITESPARK-011 trial results, […]















